26
Participants
Start Date
February 29, 2008
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
MDX-1342
One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
Columbia University Medical Center, New York
Altoona Center for Clinical Research, Duncansville
Good Samaritan Hospital and Johns Hopkins Hospital, Baltimore
Coastal Medical Research, Inc, Port Orange
Centre for Rheumatology, Immunology and Arthritis (CRIA), Fort Lauderdale
Lovelace Scientific Resources, Venice
Justus Fiechtner, Lansing
klinikum der Universitat zu Koln, Cologne
Kharkiv Medical Academy of Postgraduate Education, City Clinical General Hospital #25, Kharkiv
Zaporizhya State Medical University, City Clinical Hopsital #6, Therapeutics Department, Zaporizhya
Zaporizhzhya Regional Clinical Hospital, Rheumatology Department, Zaporizhzhya
Klinikum rechts der Isar der TU Munchen, Munich
V.K. Gusak Institute of Urgent & Reconstructive Surgery under UAMS, Hospital Therapy and Rehabilitaiton Clinic, Donetsk
Sun Valley Arthritis Center LTD., Peoria
Impact Clinical Trials, Los Angeles
George Krick, MD, Tacoma
Arthritis Northwest Rheumatology, PLLC, Spokane
"Universitatsklinikum Carl Gustav Carus an der Technischen Universtitat Dresden", Dresden
DRC Gyógyszervizsgáló Központ Kft, Balatonfüred
Semmelweis Egyetem Altalanos Orvostudomanyi Kar-I. sz, Budapest
DEOEC Kinikai Farmakologiai Tanszek, Debrecen
First Department of Medicine, Szeged
The Kellgren Centre for Rheumatology, Manchester
Welcome Trust Clinical Research Facility, Southampton General Hospital, Southampton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY